GCP
NMRA icon

GSA Capital Partners’s Neumora Therapeutics NMRA Stock Holding History

GSA Capital Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Buy
241,110
+23,160
+11% +$44.1K 0.03% 1126
2026
Q1 		$425K Sell
217,950
-316,094
-59% -$819K 0.03% 1017
2025
Q4 		$956K Buy
534,044
+425,633
+393% +$932K 0.08% 394
2025
Q3 		$197K Sell
108,411
-795,332
-88% -$1.29M 0.02% 1436
2025
Q2 		$663K Buy
903,743
+717,030
+384% +$543K 0.05% 728
2025
Q1 		$187K Buy
+186,713
New +$320K 0.02% 1407
2024
Q2 		– Sell
-29,821
Closed -$410K – 1909
2024
Q1 		$410K Sell
29,821
-17,062
-36% -$276K 0.03% 1022
2023
Q4 		$799K Buy
+46,883
New +$575K 0.07% 511

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's NMRA Position: Q2 2026 in Review

GSA Capital Partners increased its Neumora Therapeutics (NMRA) stake by 11% in Q2 2026, buying an estimated $44.1K and bringing the position to 241,110 shares worth $410K. The position accounts for 0.03% of the portfolio, ranked #1126.

GSA Capital Partners first reported a position in NMRA in Q4 2023 and has held it in 8 quarters since. The position peaked at $956K in Q4 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • GSA Capital Partners held 241,110 shares of Neumora Therapeutics worth $410K as of Q2 2026.
  • GSA Capital Partners bought 23,160 Neumora Therapeutics shares in Q2 2026, an estimated $44.1K.
  • Neumora Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1126 holding.
  • GSA Capital Partners first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • GSA Capital Partners's Neumora Therapeutics position peaked at $956K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.